BACKGROUND: To assess the putative prognostic value of K-ras mutations in nonmucinous ovarian tumors, the authors looked for K-ras point mutations at codons 12 and 13 in 144 nonmucinous ovarian tumors. METHODS: A series of 144 consecutive, unselected, archival, nonmucinous ovarian tumors (35 benign, 12 borderline, and 97 malignant) were studied. K-ras mutations at codons 12 and 13 were determined by polymerase chain reaction using the restriction fragment length polymorphism method with mismatched nested primers. Extensive clinicopathologic and follow-up data on all patients were evaluated. RESULTS: The overall prevalence of K-ras mutations at codons 12 and 13 was 30.5% (44/144). In benign tumors, it was 20% (7/35); in borderline tumors, 25% (3/12); and in carcinomas, 35% (34/97). The presence of K-ras point mutations did not correlate with survival. Among the benign tumors, K-ras mutations were detected in three Brenner tumors with a mucinous component. CONCLUSIONS: These results indicate that K-ras mutations are not initial events in the pathogenesis of nonmucinous ovarian tumors and do not appear to be related to survival.
BACKGROUND: To assess the putative prognostic value of K-ras mutations in nonmucinous ovarian tumors, the authors looked for K-ras point mutations at codons 12 and 13 in 144 nonmucinous ovarian tumors. METHODS: A series of 144 consecutive, unselected, archival, nonmucinous ovarian tumors (35 benign, 12 borderline, and 97 malignant) were studied. K-ras mutations at codons 12 and 13 were determined by polymerase chain reaction using the restriction fragment length polymorphism method with mismatched nested primers. Extensive clinicopathologic and follow-up data on all patients were evaluated. RESULTS: The overall prevalence of K-ras mutations at codons 12 and 13 was 30.5% (44/144). In benign tumors, it was 20% (7/35); in borderline tumors, 25% (3/12); and in carcinomas, 35% (34/97). The presence of K-ras point mutations did not correlate with survival. Among the benign tumors, K-ras mutations were detected in three Brenner tumors with a mucinous component. CONCLUSIONS: These results indicate that K-ras mutations are not initial events in the pathogenesis of nonmucinous ovarian tumors and do not appear to be related to survival.
Authors: Daniela Matei; Michael W Sill; Heather A Lankes; Koen DeGeest; Robert E Bristow; David Mutch; S Diane Yamada; David Cohn; Valerie Calvert; John Farley; Emanuel F Petricoin; Michael J Birrer Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: Gong Yang; Daniel G Rosen; Zhihong Zhang; Robert C Bast; Gordon B Mills; Justin A Colacino; Imelda Mercado-Uribe; Jinsong Liu Journal: Proc Natl Acad Sci U S A Date: 2006-10-23 Impact factor: 11.205
Authors: Abhimanyu S Paraskar; Shivani Soni; Kenneth T Chin; Padmaparna Chaudhuri; Katherine W Muto; Julia Berkowitz; Michael W Handlogten; Nathan J Alves; Basar Bilgicer; Daniela M Dinulescu; Raghunath A Mashelkar; Shiladitya Sengupta Journal: Proc Natl Acad Sci U S A Date: 2010-06-23 Impact factor: 11.205
Authors: Dong Liang; Larissa Meyer; David W Chang; Jie Lin; Xia Pu; Yuanqing Ye; Jian Gu; Xifeng Wu; Karen Lu Journal: Cancer Res Date: 2010-11-30 Impact factor: 12.701
Authors: L Quaye; H Song; S J Ramus; A Gentry-Maharaj; E Høgdall; R A DiCioccio; V McGuire; A H Wu; D J Van Den Berg; M C Pike; E Wozniak; J A Doherty; M A Rossing; R B Ness; K B Moysich; C Høgdall; J Blaakaer; D F Easton; B A J Ponder; I J Jacobs; U Menon; A S Whittemore; S Krüger-Kjaer; C L Pearce; P D P Pharoah; S A Gayther Journal: Br J Cancer Date: 2009-02-24 Impact factor: 7.640